Company news

ADC Therapeutics SA news in 2025

ADC Therapeutics SA's news releases, calls and decks from 2025, newest first.

View company

ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

December 3, 2025

ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial

December 2, 2025

ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update

November 10, 2025

ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025

November 3, 2025

ADC Therapeutics to Present at November Investor Conferences

October 27, 2025

ADC Therapeutics Announces $60 Million Private Placement

October 13, 2025

ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025

August 27, 2025

ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

August 12, 2025

ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025

August 5, 2025

ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

July 1, 2025

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

June 16, 2025

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

June 12, 2025

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

June 12, 2025

ADC Therapeutics to Present at Upcoming Investor Conferences

May 15, 2025

ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

May 14, 2025

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)

May 14, 2025

ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

May 8, 2025

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

April 28, 2025

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

April 1, 2025

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

March 27, 2025

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

March 25, 2025

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025

March 20, 2025

Calls in 2025

Decks in 2025